Pharmaceutical Policy

Publications authored by CHSPR faculty and staff from 2009 to the present are listed here. Older peer-reviewed publications are usually available from individual journals and can be searched for using PubMed. Older reports published by CHSPR (from 1973) are available from the UBC Library cIRcle database. If you cannot find a specific publication, please contact us.


Balaban DY, Dhalla IA, Law MR, Bell CM. Private expenditures on brand name prescription drugs after generic entry.Appl Health Econ Health Policy. 2013 Oct;11(5):523-9. Read more

Mintzes B, Lexchin J, Sutherland JM, Beaulieu MD, Wilkes MS, Durrieu G, Reynolds E. Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States. J Gen Intern Med. 2013 Oct;28(10):1368-75. Read more

Morgan SG, Thomson PA, Daw JR, Friesen MK. Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers. Health Policy. 2013 Oct;112(3):248-54. Read more

Law MR, Kratzer J.  The road to competitive generic drug prices in Canada. CMAJ. 2013 Sep 17;185(13):1141-4. Read more

Kratzer J, McGrail K, Strumpf E, Law MR. Cost-control mechanisms in Canadian private drug plans. Healthc Policy. 2013 Aug;9(1):35-43. Read more

Morgan S, Daw J, Law M. Rethinking Pharmacare in Canada. Toronto (ON): C.D. Howe Institute; Jun 2013. Commentary no.384. Read more

Morgan SG, Friesen MK, Thomson PA, Daw JR. Use of product listing agreements by Canadian provincial drug benefit plans. Healthc Policy. 2013 May;8(4):45-55. Read more

Allin S, Law MR, Laporte A. How does complementary private prescription drug insurance coverage affect seniors' use of publicly funded medications? Health Policy. 2013 May;110(2-3):147-55. Read more

Daw JR, Morgan SG, Thomson PA, Law MR. Here today, gone tomorrow: the issue attention cycle and national print media coverage of prescription drug financing in Canada. Health Policy. 2013 Apr;110(1):67-75. Read more

Morgan S, Daw J, Thomson P. International best practices for negotiating 'reimbursement contracts' with price rebates from pharmaceutical companies. Health Aff (Millwood). 2013 Apr;32(4):771-7. Read more

Law MR. Money left on the table: generic drug prices in Canada. Healthc Policy. 2013 Feb;8(3):17-25. Read more

Morgan SG, Thomson PA, Daw JR, Friesen MK. Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces. BMC Health Serv Res. 2013 Jan 31;13:34. Read more

Allin S, Bayoumi AM, Law MR, Laporte A. Comparability of self-reported medication use and pharmacy claims data. Health Rep. 2013 Jan 16;24(1):3-9. Read more

Law MR, Heard D, Fisher J, Douillard J, Muzika G, Sketris IS. The geographic accessibility of pharmacies in Nova Scotia. Can Pharm J (Ott). 2013 Jan;146(1):39-46. Read more

So L, Morgan SG, Quan H. Does concordance between survey responses and administrative records differ by ethnicity for prescription medication? J Popul Ther Clin Pharmacol. 2012;19(2):e248-58. Read more

Law M. Canadians pay too much for generic drugs. In: Roos N, Manson Singer S, O’Grady K, Tapp C, Turczak S. Canadian health policy in the news: why evidence matters. University of Manitoba: Evidence Network, 2012; 334-37. Read more

Morgan SG, Thomson PA, Daw JR, Friesen MK, Dijkstra A. The public provision of pharmaceuticals: a synthesis of policies in ten developed countries. Vancouver (BC): Pharmaceutical Policy Research Collaboration; Dec 2012. Read more

Morgan SG, Cunningham C, Law MR. Drug development: innovation or imitation deficit? BMJ. 2012 Sep 4;345:e5880. Read more

Puyat JH, Law MR, Wong ST, Sutherland JM, Morgan SG. The essential and potentially inappropriate use of antipsychotics across income groups: an analysis of linked administrative data. Can J Psychiatry. 2012 Aug;57(8):488-95. Read more

Morgan SG, Daw JR. Canadian pharmacare: looking back, looking forward. Healthc Policy. 2012 Aug;8(1):14-23. Read more